8-K/A: Neurocrine Biosciences Completes Soleno Acquisition Financials

Neurocrine Biosciences files an 8-K/A amendment to include audited and unaudited financial statements for Soleno Therapeutics and pro forma combined financial information following the acquisition.

Summary

• This filing is an amendment to a previous 8-K report, providing updated financial information related to the acquisition of Soleno Therapeutics, Inc. by Neurocrine Biosciences, Inc.
• The amendment includes the audited consolidated financial statements of Soleno for the year ended December 31, 2025, and unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026.
• It also incorporates unaudited pro forma condensed combined financial information, presenting the combined company's income statements for the six months ended June 30, 2026, and the year ended December 31, 2025.
• The acquisition, completed on May 18, 2026, added VYKAT XR (diazoxide choline) to Neurocrine's portfolio.
• A $1.0 billion senior secured revolving credit facility was entered into on May 14, 2026, with $600.0 million drawn and repaid within the period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it provides necessary financial disclosures for a completed acquisition and a credit facility, but lacks new operational or strategic updates beyond the transaction itself.

Positives

• Successful completion of the acquisition of Soleno Therapeutics, adding VYKAT XR to Neurocrine's portfolio.
• Pro forma combined revenues of $1,907.5 million for the six months ended June 30, 2026, and $3,050.9 million for the year ended December 31, 2025.
• Pro forma combined net income of $294.0 million for the six months ended June 30, 2026, and $324.5 million for the year ended December 31, 2025.
• Pro forma diluted EPS of $2.83 for the six months ended June 30, 2026, and $3.17 for the year ended December 31, 2025.

Negatives

• Pro forma combined operating loss of $(76.3) million for the three months ended March 31, 2026 (derived from Soleno's historical data).
• Significant pro forma transaction accounting adjustments, including $53.6 million and $139.9 million in amortization of acquired intangible assets for the six months ended June 30, 2026, and the year ended December 31, 2025, respectively.
• Amortization of fair-value step-up to inventory resulted in an increase to cost of revenues of $15.1 million and $28.8 million for the respective periods.
• Reclassification of interest income to investment income and other, net, and reclassification of Soleno's departmental expense classifications within operating expenses.

Risks

• Preliminary estimates for fair values of acquired assets and liabilities, and resulting goodwill, may differ from final calculations.
• Future results of the combined company may differ significantly from pro forma amounts due to integration efforts, market conditions, and differences in purchase price allocation.
• A 10% change in the valuation of intangible assets could impact amortization expense by approximately $7.0 million and $13.9 million for the six months ended June 30, 2026, and the year ended December 31, 2025, respectively.
• The pro forma financial information does not reflect any revenue synergies or cost savings that may result from the acquisition.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the pro forma financial information, which is presented for illustrative purposes and does not necessarily indicate future results. The company intends to finalize acquisition accounting within one year.

Industry Context

StockSavvy.ai notes that this filing reflects a significant strategic move by Neurocrine Biosciences to expand its rare disease and endocrinology portfolio through the acquisition of Soleno Therapeutics and its lead asset VYKAT XR. This aligns with industry trends of consolidation and targeted acquisitions to bolster pipeline and market position in specialized therapeutic areas.

Stakeholder Impact

• Shareholders: The acquisition of Soleno and the associated financial disclosures are expected to provide clarity on the combined entity's financial position and future prospects.
• Creditors: The establishment of a $1.0 billion credit facility indicates potential leverage and financing strategies for the combined company.
• Employees: Integration of Soleno's operations may lead to changes in organizational structure and roles within the combined entity.

Next Steps

• Finalize acquisition accounting within one year of the closing date.
• Continue integration efforts and market development for VYKAT XR.

Key Dates

Keywords

Acquisition, Merger, Financial Statements, Pro Forma, Soleno Therapeutics, Neurocrine Biosciences, VYKAT XR, Diazoxide Choline